Aller au contenu

The European Hematology Association 24th congress EHA 2019

13 Juin 2019 · 4 joursAmsterdam, Pays-BasHématologieAnglais
The European Hematology Association 24th congress EHA 2019
Amsterdam

À propos de ce congrès

From 13-16 June 2019, the European Hematology Association (EHA) Congress will take place for the 24th time. EHA is known as the premier hematology congress in Europe and offers a congress program covering every sub-specialty in hematology and the opportunity to network with experts from all over the globe. The educational and scientific program highlights state-of-the art clinical practice, the latest findings and innovations in hematology research.
The congress also provides you with the opportunity to attend satellite programs, Updates-in-Hematology and to visit the exhibition organized by pharmaceutical companies.

MEDFLIXS couvrira les temps forts de ce congrès sous forme d'interviews vidéo et de best-of disponibles pour les professionnels de santé inscrits.

Vidéos de ce congrès

Pierre Fenaux · Imetelstat provides durable transfusion independence in heavily transfused
Lancer la vidéo · Pierre Fenaux · Imetelstat provides durable transfusion independence in heavily transfusedInscription gratuite requise pour lancer la lecture

Pierre Fenaux · 00:09:35

Maria-Victoria Mateos · Myeloma highlights from EHA 2019
Lancer la vidéo · Maria-Victoria Mateos · Myeloma highlights from EHA 2019Inscription gratuite requise pour lancer la lecture

Maria-Victoria Mateos · 00:05:35

Philippe Moreau · D-VTd in induction prior to and consolidation after ASCT improves PFS
Lancer la vidéo · Philippe Moreau · D-VTd in induction prior to and consolidation after ASCT improves PFSInscription gratuite requise pour lancer la lecture

Philippe Moreau · 00:05:39

Mohamad Mohty · CAR T Cells for treating acute leukaemia
Lancer la vidéo · Mohamad Mohty · CAR T Cells for treating acute leukaemiaInscription gratuite requise pour lancer la lecture

Mohamad Mohty · 00:03:02

Kirsten Fischer · Venetoclax plus obinutuzumab improves PFS and MRD-negativity
Lancer la vidéo · Kirsten Fischer · Venetoclax plus obinutuzumab improves PFS and MRD-negativityInscription gratuite requise pour lancer la lecture

Kirsten Fischer · 00:10:44

Christopher Hourigan · Intervention for AML patients with MRD can result in improved survival
Lancer la vidéo · Christopher Hourigan · Intervention for AML patients with MRD can result in improved survivalInscription gratuite requise pour lancer la lecture

Christopher Hourigan · 00:10:37

Etienne De Braekeleer · Inhibition of NADK strongly inhibits T-ALL cells from growing
Lancer la vidéo · Etienne De Braekeleer · Inhibition of NADK strongly inhibits T-ALL cells from growingInscription gratuite requise pour lancer la lecture

Etienne De Braekeleer · 00:06:48

Mark Roschewski · Novel immunotherapy 5F9+rituximab well tolerated with rapid and durable responses
Lancer la vidéo · Mark Roschewski · Novel immunotherapy 5F9+rituximab well tolerated with rapid and durable responsesInscription gratuite requise pour lancer la lecture

Mark Roschewski · 00:12:34

Mohamad Mohty · Multiple myeloma science from EHA 2019
Lancer la vidéo · Mohamad Mohty · Multiple myeloma science from EHA 2019Inscription gratuite requise pour lancer la lecture

Mohamad Mohty · 00:04:40

Anton Hagenbeek · Comment on fixed-duration venetoclax plus obinutuzumab in patients with CLL and comorbidities
Lancer la vidéo · Anton Hagenbeek · Comment on fixed-duration venetoclax plus obinutuzumab in patients with CLL and comorbiditiesInscription gratuite requise pour lancer la lecture

Anton Hagenbeek · 00:01:25

Anton Hagenbeek · Comment on pregnancy outcomes in patients with chronic myeloid leukaemia
Lancer la vidéo · Anton Hagenbeek · Comment on pregnancy outcomes in patients with chronic myeloid leukaemiaInscription gratuite requise pour lancer la lecture

Anton Hagenbeek · 00:01:41

Mark Roschewski · Safety and efficacy of escalating doses of the hu5f9-g4 with rituximab in patients
Lancer la vidéo · Mark Roschewski · Safety and efficacy of escalating doses of the hu5f9-g4 with rituximab in patientsInscription gratuite requise pour lancer la lecture

Mark Roschewski · 00:05:26